Key Takeaways
- Demand recovery underway, summer drags: Non-summer categories like Pain Management and Healthcare returned to double-digit growth, but unseasonal rains hit the summer portfolio, pulling down Navratna by 8%.
- Gross margin tailwind of 240 bps: Softening raw material prices expanded gross margin to 65.4%, creating leverage the company plans to reinvest in advertising and margin delivery.
- Modern Trade and e-commerce now 20% of sales: Having entered these channels late, management expects them to grow 15–20% going forward and reach a 25–26% mix in 2–3 years, with a sharp focus on narrowing their margin gap to General Trade.
- International business is a stable, profitable growth engine: Driven by big brands and regional advertising, it is expected to maintain its trajectory and grow ~15% long-term, despite near-term currency headwinds in Russia and Egypt.
- What to watch next quarter: Whether the winter season is good enough to trigger the planned 1% A&P step-up, the pace of throughput improvement from Project Khoj’s expanded direct coverage, and closure of the hospital transaction.
Summer Season & Portfolio Performance
- Unseasonal rains hurt summer categories: The Navratna range declined 8% as the summer season was disrupted across the country, impacting sales of summer products broadly.
- Dermicool grew 9% despite the bad season: Distribution initiatives undertaken after the acquisition drove growth; management believes growth would have exceeded 18–20% in a normal summer.
- Cooling oil market share intact: Management pushed back on competitor claims, stating the company has not lost even 0.1% market share in cooling oil and attributing softness entirely to the season.
- Male Grooming flat on a high base: The category faced a very high base in the first four months of last year; management is very confident of double-digit growth from Q2 onwards.
- No plan to deseasonalize: The company looks at gaps through a consumer lens and will fill them where it can make money, as demonstrated by the acquisition of the seasonal brand Dermicool.
Mohan Goenka: "We haven't lost even 0.1% market share in the cooling oil. So, unfortunately, the season was bad, which you all are aware."
Channel Mix & Distribution
- Modern Trade and e-commerce reached ~20% contribution: The company entered these channels late but has been focusing on them for 8–10 quarters, launching exclusive SKUs and promotions. Management now expects these channels to grow 15–20%.
- Long-term channel mix target of 25–26%: Expected within 2–3 years, in line with peers already at that level; the mix is then expected to stabilize at 25–26% long-term.
- Margin gap in modern trade and e-commerce to narrow: This year’s primary focus is expanding margins in these channels; management declined to quantify the gap but said it will narrow substantially this year.
- General Trade is flat, not declining: The apparent decline is driven entirely by the summer portfolio, particularly Navratna sachets which are primarily a GT brand.
- Project Khoj completed, now shifting to throughput: The two-year initiative expanded direct coverage to almost 10 lakh outlets across e-com, modern trade, chemist outlets and rural. The next challenge is increasing throughput from these outlets using trade marketing and analytics.
Mohan Goenka: "This year our focus has been primarily on expanding margins in modern trade and e-commerce."
Margins & Investment
- Gross margin expanded 240 bps to 65.4%: Driven by softening of key raw material prices, with further improvement expected going ahead.
- EBITDA margin expected to expand 200–250 bps for FY24: Management committed to at least this level of YoY expansion on the current basis, even as it reinvests some of the gross margin tailwind.
- A&P spend reallocated, with a conditional step-up: Advertising was reduced in the summer portfolio and increased elsewhere. A further 1% A&P increase is contingent on a good winter season; management will wait and watch before committing.
- Most Project Khoj investment is complete: With the distribution expansion largely done, the majority of gross margin tailwinds will flow to A&P rather than fixed-cost investments.
- Depreciation and amortization run-rate: Expected to settle in the INR45–50 crore range going ahead, split roughly between INR23–24 crore of amortization and INR20 crore of depreciation.
Mohan Goenka: "We will be very careful. We will wait and watch how the winter pans out to be. If the winter is good, then we would definitely increase A&P by 1%. But overall, despite of that, we expect margins to increase by at least 200 basis points, 250 basis points."
Healthcare & Digital
- Healthcare range returned to double-digit growth: Pain Management and Healthcare saw a sequential demand recovery with moderating inflation.
- OTC focus driving results: The company is focusing on vitality, digestives and other health supplements not dependent on season or COVID-period demand, with more aggressive advertising in focus categories.
- Doctor coverage has room to expand: About one-third of covered doctors are allopathic and the rest Ayurvedic; coverage is lower than some competitors, leaving scope to improve both coverage and throughput per doctor.
- D2C platform zanducare.com ramping up: Focus is on launching digital-first products rather than legacy ones; digital contribution in Healthcare is around 10% and scaling.
- The Man Company turned breakeven: The subsidiary achieved no negative EBITDA this quarter, a milestone in its trajectory.
International Business
- Growth driven by big brands and regional focus: Existing markets and major brands are the primary growth drivers, supported by strong, regionally focused advertising. Innovations are still being seeded for future growth.
- Profitability enables higher investment: International business gives good profitability, so investment has gone up significantly, and a lot of stability has come in.
- Currency headwinds in specific markets: Russia is facing sharp currency depreciation over the last 3–4 months, and Egypt was particularly bad this quarter.
- Consumer base is predominantly non-Indian: Russia CIS, Bangladesh, OTC in Africa and Myanmar are largely local consumers; Southeast Asia and GCC have a mix of Indian and local consumers.
- Long-term growth expectation of ~15%: Management expects the international business to maintain its growth trajectory and post even better results in the next 9 months.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin expansion | At least 200–250 bps YoY expansion | Full year FY24 |
| Modern Trade and e-commerce growth | 15–20% growth from current ~20% contribution | Ongoing |
| Modern Trade and e-commerce mix | Reach 25–26% of sales | Next 2–3 years |
| Male Grooming growth | Double-digit growth | From Q2 FY24 onwards |
| International business growth | ~15% long-term growth | Long-term |
| Healthcare growth | Double-digit growth | Ongoing |
| Kesh King growth | ~7–8% growth | Next 2–3 years |
| Innovation contribution | ~3% of sales | Full year FY24 |
| Hospital transaction closure | Transaction completed | By end of current month |
| A&P step-up | Increase A&P by 1% | Conditional on a good winter season |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Consolidated revenue | ~7% growth YoY |
| Domestic volume growth | 3% |
| Gross margin | 65.4%, expanded 240 bps YoY |
| EBITDA | ₹190 cr, +10% YoY; margin at 23%, expanded 60 bps YoY |
| Profit after tax | ₹138 cr, +87% YoY |
| Adjusted PAT | ₹161 cr, +17% YoY |
| EBITDA margin guidance (FY24) | At least 27.5%, +200-250 bps YoY (per an analyst's math) |
| Pain Management growth | 13% |
| Healthcare range growth | 11% |
| Boro Plus range growth | 19% |
| Navratna range growth | -8% |
| Dermicool growth | 9% |
| Kesh King growth | 2% |
| Male grooming range growth | Flat |
| Modern Trade growth | 45% |
| E-commerce growth | 47% |
| Modern Trade and e-commerce saliency | 19.4% of domestic sales, +510 bps YoY |
| International business growth | 8% reported, 11% constant currency |
| International business growth ex-Egypt | ~20% constant currency |
| A&P spend growth | 11% |
| Depreciation and amortization | ₹46 cr (includes ₹16 cr Brillare write-off) |
| Innovation contribution | ~2.5% of revenue in Q1; FY24 expected ~3% |
| D2C/acquired companies (TMC, Brillare) contribution | 4-5% of sales in FY24 |
| TMC and Brillare growth | ~27% |
| Pledge level | 33% currently; expected 18-20% post-hospital transaction |
| MAT credit balance | ~₹300 cr as of June 23 |
| Summer portfolio contribution | ~41% of Q1 sales |